Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid

C. Jacobs, C. N. Coleman, L. Rich, K. Hirst, M. W. Weiner

Research output: Contribution to journalArticle

Abstract

The renal handling of cis-diamminedichloroplatinum (CP) was investigated by measuring the renal clearance of creatinine, inulin, and free platinum in ten cancer patients. Free platinum clearances exceeded the glomerular filtration rate in all time periods. For example, at 1 to 2 hr, the mean clearance of free platinum was 224 ± 32 (S.E.) ml/min compared to a mean creatinine clearance of 94 ± 15 ml/min or a mean inulin clearance of 94 ± 17 ml/min (p <0.01), indicating secretion of CP or a metabolite. Seven additional cancer patients were treated with probenecid prior to CP. Fractional platinum clearances, calculated as a ratio of free platinum clearance to creatinine clearance, were reduced significantly in the probenecid-treated group (158 ± 17%) compared to controls (270 ± 57%) (p = 0.03). Fractional platinum clearances, calculated as a ratio of free platinum clearance to inulin clearance, were also significantly reduced in the treated group (154 ± 14%) compared to controls (271 ± 47%) (p = 0.04). These results suggest that cisplatin is secreted by the human kidney, and this can be inhibited by probenecid. Such maneuvers may be helpful in improving the therapeutic index of this important chemotherapeutic agent.

Original languageEnglish (US)
Pages (from-to)3632-3635
Number of pages4
JournalCancer Research
Volume44
Issue number8
StatePublished - 1984
Externally publishedYes

Fingerprint

Probenecid
Platinum
Cisplatin
Kidney
Inulin
Creatinine
Glomerular Filtration Rate
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jacobs, C., Coleman, C. N., Rich, L., Hirst, K., & Weiner, M. W. (1984). Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Research, 44(8), 3632-3635.

Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. / Jacobs, C.; Coleman, C. N.; Rich, L.; Hirst, K.; Weiner, M. W.

In: Cancer Research, Vol. 44, No. 8, 1984, p. 3632-3635.

Research output: Contribution to journalArticle

Jacobs, C, Coleman, CN, Rich, L, Hirst, K & Weiner, MW 1984, 'Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid', Cancer Research, vol. 44, no. 8, pp. 3632-3635.
Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW. Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Research. 1984;44(8):3632-3635.
Jacobs, C. ; Coleman, C. N. ; Rich, L. ; Hirst, K. ; Weiner, M. W. / Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. In: Cancer Research. 1984 ; Vol. 44, No. 8. pp. 3632-3635.
@article{96841429e31f4f1d85eb2ace4772b6e3,
title = "Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid",
abstract = "The renal handling of cis-diamminedichloroplatinum (CP) was investigated by measuring the renal clearance of creatinine, inulin, and free platinum in ten cancer patients. Free platinum clearances exceeded the glomerular filtration rate in all time periods. For example, at 1 to 2 hr, the mean clearance of free platinum was 224 ± 32 (S.E.) ml/min compared to a mean creatinine clearance of 94 ± 15 ml/min or a mean inulin clearance of 94 ± 17 ml/min (p <0.01), indicating secretion of CP or a metabolite. Seven additional cancer patients were treated with probenecid prior to CP. Fractional platinum clearances, calculated as a ratio of free platinum clearance to creatinine clearance, were reduced significantly in the probenecid-treated group (158 ± 17{\%}) compared to controls (270 ± 57{\%}) (p = 0.03). Fractional platinum clearances, calculated as a ratio of free platinum clearance to inulin clearance, were also significantly reduced in the treated group (154 ± 14{\%}) compared to controls (271 ± 47{\%}) (p = 0.04). These results suggest that cisplatin is secreted by the human kidney, and this can be inhibited by probenecid. Such maneuvers may be helpful in improving the therapeutic index of this important chemotherapeutic agent.",
author = "C. Jacobs and Coleman, {C. N.} and L. Rich and K. Hirst and Weiner, {M. W.}",
year = "1984",
language = "English (US)",
volume = "44",
pages = "3632--3635",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid

AU - Jacobs, C.

AU - Coleman, C. N.

AU - Rich, L.

AU - Hirst, K.

AU - Weiner, M. W.

PY - 1984

Y1 - 1984

N2 - The renal handling of cis-diamminedichloroplatinum (CP) was investigated by measuring the renal clearance of creatinine, inulin, and free platinum in ten cancer patients. Free platinum clearances exceeded the glomerular filtration rate in all time periods. For example, at 1 to 2 hr, the mean clearance of free platinum was 224 ± 32 (S.E.) ml/min compared to a mean creatinine clearance of 94 ± 15 ml/min or a mean inulin clearance of 94 ± 17 ml/min (p <0.01), indicating secretion of CP or a metabolite. Seven additional cancer patients were treated with probenecid prior to CP. Fractional platinum clearances, calculated as a ratio of free platinum clearance to creatinine clearance, were reduced significantly in the probenecid-treated group (158 ± 17%) compared to controls (270 ± 57%) (p = 0.03). Fractional platinum clearances, calculated as a ratio of free platinum clearance to inulin clearance, were also significantly reduced in the treated group (154 ± 14%) compared to controls (271 ± 47%) (p = 0.04). These results suggest that cisplatin is secreted by the human kidney, and this can be inhibited by probenecid. Such maneuvers may be helpful in improving the therapeutic index of this important chemotherapeutic agent.

AB - The renal handling of cis-diamminedichloroplatinum (CP) was investigated by measuring the renal clearance of creatinine, inulin, and free platinum in ten cancer patients. Free platinum clearances exceeded the glomerular filtration rate in all time periods. For example, at 1 to 2 hr, the mean clearance of free platinum was 224 ± 32 (S.E.) ml/min compared to a mean creatinine clearance of 94 ± 15 ml/min or a mean inulin clearance of 94 ± 17 ml/min (p <0.01), indicating secretion of CP or a metabolite. Seven additional cancer patients were treated with probenecid prior to CP. Fractional platinum clearances, calculated as a ratio of free platinum clearance to creatinine clearance, were reduced significantly in the probenecid-treated group (158 ± 17%) compared to controls (270 ± 57%) (p = 0.03). Fractional platinum clearances, calculated as a ratio of free platinum clearance to inulin clearance, were also significantly reduced in the treated group (154 ± 14%) compared to controls (271 ± 47%) (p = 0.04). These results suggest that cisplatin is secreted by the human kidney, and this can be inhibited by probenecid. Such maneuvers may be helpful in improving the therapeutic index of this important chemotherapeutic agent.

UR - http://www.scopus.com/inward/record.url?scp=0021154184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021154184&partnerID=8YFLogxK

M3 - Article

C2 - 6540140

AN - SCOPUS:0021154184

VL - 44

SP - 3632

EP - 3635

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -